Search
Axsome Therapeutics Inc
AXSMAdd to Watchlist
241.120USD
-0.550-0.23%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
12.41BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.23%
5 Days
-2.72%
1 Month
+2.83%
6 Months
+60.02%
Year to Date
+32.02%
1 Year
+133.28%
Key Figures
244.080Open
248.154High
1.36MVolume
LossP/E TTM
37.74P/E Dynamic
--Dividend TTM
2.64%Turnover Ratio
241.670Prev. Close
236.470Low
261.81MTurnover
LossP/E Static
227.13P/B
0.00%Div Yield TTM
-28.74%ROA
238.56052wk High
0.57Volume Ratio
-287.22MNet Profit
51.42MShares
-3.7270EPS TTM
0.60Beta
-349.38%ROE
96.09052wk Low
4.83%Amplitude
91.48%Gross Margin
12.41BMarket Cap
1.29Reward/Risk
2.38%Risk Rate
TradingKey Stock Score of Axsome Therapeutics Inc
Currency: USD Updated: 2026-06-29Key Insights
Axsome Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 273.85.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Axsome Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Axsome Therapeutics Inc Highlights
StrengthsRisks
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 135.96% year-on-year.
Undervalued
The company’s latest PE is -64.70, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.43M shares, decreasing 8.10% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 67.76K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
273.850
Target Price
+13.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Axsome Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Axsome Therapeutics Inc Info
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Ticker SymbolAXSM
CompanyAxsome Therapeutics Inc
CEOTabuteau (Herriot)
Websitehttps://www.axsome.com/
Related Instruments
+1.74%
+1.48%
+0.30%
+0.56%
+1.38%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
52274.000
+120.800 (+0.23%)
29791.900
+84.200 (+0.28%)
7443.200
+11.000 (+0.15%)
15578.000
+127.000 (+0.82%)
69814.000
-660.000 (-0.94%)
6297.200
+41.400 (+0.66%)
70.951
+0.635 (+0.90%)
281.740
-2.040 (-0.72%)
194.970
+2.440 (+1.27%)
4025.250
+9.660 (+0.24%)
FAQs
What is the current price of Axsome Therapeutics Inc (AXSM)?
The current price of Axsome Therapeutics Inc (AXSM) is 241.12.
What is the symbol of Axsome Therapeutics Inc?
The ticker symbol of Axsome Therapeutics Inc is AXSM.
What is the 52-week high of Axsome Therapeutics Inc?
The 52-week high of Axsome Therapeutics Inc is 238.56.
What is the 52-week low of Axsome Therapeutics Inc?
The 52-week low of Axsome Therapeutics Inc is 96.09.
What is the market capitalization of Axsome Therapeutics Inc?
The market capitalization of Axsome Therapeutics Inc is 12.40B.
Is Axsome Therapeutics Inc (AXSM) currently rated as Buy, Hold, or Sell?
According to analysts, Axsome Therapeutics Inc (AXSM) has an overall rating of Buy, with a price target of 273.85.
What is the Earnings Per Share (EPS TTM) of Axsome Therapeutics Inc (AXSM)?
The Earnings Per Share (EPS TTM) of Axsome Therapeutics Inc (AXSM) is -3.68.
